Flerie Invest gains control of Xintela with board seat and bridge financing

Flerie Invest Consolidates Control of Xintela, Providing Crucial Support

• Flerie Invest has built a controlling stake in Xintela and placed its founder on the board, signaling strong backing for the company’s clinical-stage pipeline.
• Bridge financing from Flerie has helped sustain Xintela’s ongoing Phase I/IIa trials for its lead stem cell product, though the company’s long-term funding remains unsecured.
• A strategic manufacturing framework agreement with NorthX Biologics – where Flerie’s founder also serves as Chairman – points to aligned interests in scaling production capabilities.
• The presence of a going-concern uncertainty in recent annual filings underscores the importance of this blockholder support for Xintela’s near-term operations.